10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

10x Genomics, Inc.NASDAQ: TXG

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns positive

Q3 FY2026 income tax expense was $949K, compared with -$733K a year earlier. Trailing-twelve-month income tax expense was $1.92M. Over 3 fiscal years it compounded at -3.4% a year.

Context

  • Income tax expense amounted to 0.6% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $949K or moves back toward the trailing-twelve-month quarterly average of $479.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$949K+232.9% QoQ
Last fiscal yearDec 2025
$3.64M-26.2% YoY
LTMSep 2026
$1.92M-40.6% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+229.5%——
1 year-26.2%——
3-year CAGR-3.4%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
3.64M USD
Year-over-year change
-26.2%
4-year CAGR
-5.2%

Income Tax Expense vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's LTM Sep 2026 income tax expense of $1.92M is the 7th highest of the 9 companies compared; the peer median is $53.96M.
  • Its year-over-year change of -40.6% is the 5th highest of 9, against a peer median of -23.2%.
  • Income tax expense amounts to 0.3% of revenue for TXG, versus a peer median of 3.6%.
TXG Competitors Peer median
Income Tax Expense for TXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$218M +25.3%-19.2%3.0%
ILMNIllumina, Inc.LTM Jun 2026$190M +37.7%+51.4%4.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$128M -2.3%—4.9%
TECHBio-Techne CorporationLTM Sep 2026$55.41M +95.8%+3.4%4.5%
QGENQiagen N.V.LTM Jun 2026$52.51M -54.5%-9.9%2.5%
RVTYRevvity, Inc.LTM Jul 2026$20.81M -44.2%-43.0%0.7%
TXG10x Genomics, Inc.LTM Sep 2026$1.92M -40.6%-3.4%0.3%
TWSTTwist Bioscience CorporationLTM Sep 2026-$406K -156.5%—0.1%
LABStandard BioTools Inc.LTM Mar 2026-$37.75M -12276.1%—43.8%
Peer median (excluding TXG) $53.96M-23.2%-9.9%3.6%

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue490.49M516.41M618.73M610.79M642.82M
Cost of Revenue74.09M120.39M209.41M196.3M198.94M
Gross Profit416.4M396.02M409.31M414.48M443.88M
Gross Margin84.9%76.7%66.2%67.9%69.1%
Research & Development211.75M265.67M270.33M264.7M238.63M
Selling, General & Admin257.56M298.3M343.33M344.34M316.13M
Operating Expenses469.31M563.97M674.64M609.04M554.77M
Depreciation & Amortization28.25M33.01M43.62M43.71M43.82M
EBITDA(24.6M)(128.49M)(205.11M)(133.99M)3.91M
EBITDA Margin-5.0%-24.9%-33.2%-21.9%0.6%
Operating Income(52.91M)(167.94M)(265.33M)(194.56M)(110.89M)
Operating Margin-10.8%-32.5%-42.9%-31.9%-17.2%
Interest Income206K6.65M16.91M18.45M20.05M
Interest Expense866K476K33K4K0
Other Income / Expenses(802K)5.97M16.57M16.86M70.98M
Income Before Tax(53.72M)(161.97M)(248.76M)(177.7M)(39.91M)
Pre-Tax Margin-11.0%-31.4%-40.2%-29.1%-6.2%
Income Tax Expense4.51M4.03M6.34M4.93M3.64M
Net Income(58.22M)(166M)(255.1M)(182.63M)(43.54M)
Net Margin-11.9%-32.1%-41.2%-29.9%-6.8%
EPS (Basic)(0.53)(1.46)(2.18)(1.52)(0.35)
EPS (Diluted)(0.53)(1.46)(2.18)(1.52)(0.35)
Weighted Avg Shares110.35M113.86M117.17M120.45M124.75M
Weighted Avg Shares (Diluted)110.35M113.86M117.17M120.45M124.75M

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.